2023-02-28
Computational repurposing and preclinical validation of colquhounia root tablets for membranous nephropathy
2023-02-28 • Xia Mao, Kexin Wang, Yudong Liu, Xiao-Hui Su, Anguo Wu, Lin Chen, Jiangrui Wang, Beilei Cai, Yanqiong Zhang, Feng Huang, Na Lin
Current therapeutics of membranous nephropathy (MN) hold dilemmas of limited clinical response rates, high recurrence rate, and unavoidable adverse effects.1 Colquhounia Root Tablet (CRT) is a Chinese patent medicine prepared from the peeled root of Tripterygium hypoglaucum (Lévl.) Hutch (SFDA approval number: Z20027411). Emerging clinical evidence has indicated a potential therapeutic effect of CRT on MN.2, 3 However, the mechanisms of CRT against MN remain unclear. In this study, 585 putative targets of CRT were…